SG11202106986VA - L718 and/or l792 mutant treatment-resistant egfr inhibitor - Google Patents

L718 and/or l792 mutant treatment-resistant egfr inhibitor

Info

Publication number
SG11202106986VA
SG11202106986VA SG11202106986VA SG11202106986VA SG11202106986VA SG 11202106986V A SG11202106986V A SG 11202106986VA SG 11202106986V A SG11202106986V A SG 11202106986VA SG 11202106986V A SG11202106986V A SG 11202106986VA SG 11202106986V A SG11202106986V A SG 11202106986VA
Authority
SG
Singapore
Prior art keywords
egfr inhibitor
resistant egfr
mutant treatment
mutant
treatment
Prior art date
Application number
SG11202106986VA
Inventor
Shinichi Hasako
Takao Uno
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11202106986VA publication Critical patent/SG11202106986VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202106986VA 2018-12-28 2019-12-27 L718 and/or l792 mutant treatment-resistant egfr inhibitor SG11202106986VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018247131 2018-12-28
PCT/JP2019/051377 WO2020138400A1 (en) 2018-12-28 2019-12-27 L718 and/or l792 mutant treatment-resistant egfr inhibitor

Publications (1)

Publication Number Publication Date
SG11202106986VA true SG11202106986VA (en) 2021-07-29

Family

ID=69174561

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106986VA SG11202106986VA (en) 2018-12-28 2019-12-27 L718 and/or l792 mutant treatment-resistant egfr inhibitor

Country Status (13)

Country Link
US (1) US20220072000A1 (en)
EP (1) EP3902548A1 (en)
JP (1) JP7303303B2 (en)
KR (1) KR20210110329A (en)
CN (1) CN113423403A (en)
AU (1) AU2019417691A1 (en)
BR (1) BR112021012687A2 (en)
CA (1) CA3124750A1 (en)
IL (1) IL284330A (en)
MX (1) MX2021007852A (en)
SG (1) SG11202106986VA (en)
WO (1) WO2020138400A1 (en)
ZA (1) ZA202104679B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096372A (en) * 2020-07-09 2023-05-09 上海和誉生物医药科技有限公司 EGFR inhibitor, preparation method and pharmaceutical application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600759XA (en) * 2013-08-22 2016-03-30 Taiho Pharmaceutical Co Ltd Novel quinoline-substituted compound
EP3143015B1 (en) 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
JOP20190073A1 (en) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd Selective inhibitor of exon 20 insertion mutant egfr
CN111465397B (en) 2017-09-01 2023-10-13 大鹏药品工业株式会社 Selective inhibitors of EGFR mutant at exon 18 and/or exon 21

Also Published As

Publication number Publication date
ZA202104679B (en) 2023-12-20
KR20210110329A (en) 2021-09-07
JP7303303B2 (en) 2023-07-04
JP2022522573A (en) 2022-04-20
CA3124750A1 (en) 2020-07-02
TW202038965A (en) 2020-11-01
IL284330A (en) 2021-08-31
AU2019417691A1 (en) 2021-07-22
BR112021012687A2 (en) 2021-09-28
CN113423403A (en) 2021-09-21
WO2020138400A1 (en) 2020-07-02
EP3902548A1 (en) 2021-11-03
US20220072000A1 (en) 2022-03-10
MX2021007852A (en) 2021-08-11

Similar Documents

Publication Publication Date Title
IL290399A (en) Kras g12c inhibitors and methods of using the same
IL272512A (en) Inhibitors of kras g12c and methods of using the same
IL276095A (en) Gcn2 inhibitors and uses thereof
IL276147A (en) Gcn2 inhibitors and uses thereof
ZA202002172B (en) Pde9 inhibitor and use thereof
EP3587419A4 (en) Fgfr inhibitor and application thereof
EP3572400C0 (en) Ezh2 inhibitor and use thereof
IL276489A (en) Atr inhibitor and application thereof
PT3677266T (en) Exon 18 and/or exon 21 mutant egfr selective inhibitor
IL282350A (en) Rgmc-selective inhibitors and use thereof
GB2591554B (en) Composiitons and methods and uses relating thereto
ZA202102192B (en) Fgfr4 inhibitor and use thereof
IL286485A (en) Pi4-kinase inhibitors and methods of using the same
IL284330A (en) L718 and/or l792 mutant treatment-resistant egfr inhibitor
EP3744722A4 (en) ß-LACTAMASE INHIBITOR AND USE THEREOF
IL280408A (en) Cdk inhibitors and uses thereof
GB2589437B (en) Circuitry and methods
GB201908884D0 (en) Inhibitors and use
GB201902266D0 (en) New methods and uses
GB201919187D0 (en) Kits and devices
GB201812776D0 (en) New methods and uses